AstraZeneca plans to deliver vaccine in September

AstraZeneca could supply by September the first doses of a coronavirus vaccine after the British-Swedish drug maker was handed more than $1bn by the US authorities to speed up development, news wires reported. The company said it had been given orders for at least 400 million doses and secured total manufacturing capacity for one billion doses so far.

AstraZeneca’s vaccine development programme includes clinical trial with 30,000 participants and a pediatric trial. CEO Pascal Soriot said the drugmaker would do everything in its power to make the vaccine “quickly and widely available.”  The University of Oxford announced it had partnered with AstraZeneca in April, to allow the drug maker to develop and distribute the vaccine being researched by the Jenner Institute and Oxford Vaccine Group.

Human trials began last month on over 1,000 volunteers in England and AstraZeneca said that data from the trials was “expected shortly which, if positive, would lead to late-stage trials in a number of countries.”  Although, given that no trial data has been released, we do not yet know if the vaccine will be effective and AstraZeneca has said it recognises that it may not work.

On Monday, US drugmaker Moderna released positive data from its phase one human trial on its potential vaccine, in development with the US government. Health-care publication STAT then reported Tuesday that vaccine experts were skeptical of Moderna’s new data. However, Moderna Chairman Noubar Afeyan told CNBC Wednesday that the drugmaker would never put out coronavirus vaccine data that was different from “reality.”

More on this subject: Coronavirus

Similar articles